Cargando…
Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy
PURPOSE: Fine-needle aspiration cytology (FNAC) of axillary lymph nodes (AxLNs) is performed to diagnose nodal metastasis in patients with breast cancer. Although the sensitivity of ultrasound-guided FNAC for identifying AxLN metastasis is in the range of 36%–99%, whether sentinel lymph node biopsy...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Breast Cancer Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139842/ https://www.ncbi.nlm.nih.gov/pubmed/37051648 http://dx.doi.org/10.4048/jbc.2023.26.e13 |
_version_ | 1785033035204263936 |
---|---|
author | Takatsuka, Daiki Yoshimura, Akiyo Sawaki, Masataka Hattori, Masaya Kotani, Haruru Kataoka, Ayumi Horisawa, Nanae Ozaki, Yuri Endo, Yuka Nozawa, Kazuki Iwata, Hiroji |
author_facet | Takatsuka, Daiki Yoshimura, Akiyo Sawaki, Masataka Hattori, Masaya Kotani, Haruru Kataoka, Ayumi Horisawa, Nanae Ozaki, Yuri Endo, Yuka Nozawa, Kazuki Iwata, Hiroji |
author_sort | Takatsuka, Daiki |
collection | PubMed |
description | PURPOSE: Fine-needle aspiration cytology (FNAC) of axillary lymph nodes (AxLNs) is performed to diagnose nodal metastasis in patients with breast cancer. Although the sensitivity of ultrasound-guided FNAC for identifying AxLN metastasis is in the range of 36%–99%, whether sentinel lymph node biopsy (SLNB) should be performed for neoadjuvant chemotherapy (NAC) patients with negative FNAC results is uncertain. This study aimed to determine the role of FNAC before NAC in the evaluation and management of AxLN in early breast cancer patients. METHODS: We retrospectively analyzed 3,810 clinically node-negative (a lymph node with no clinical metastasis without FNAC or radiological suspicion of metastasis with negative FNAC results) patients with breast cancer who underwent SLNB between 2008 and 2019. We compared the positivity rate of sentinel lymph nodes (SLNs) between patients who received and those who did not receive NAC with negative FNAC results or without FNAC and axillary recurrence rate in the neoadjuvant group with negative SLNB results. RESULTS: In the non-neoadjuvant (primary surgery) group, the positivity rate of SLNs in patients with negative FNAC results was higher than that in patients without FNAC (33.2% vs. 12.9%; p < 0.001). However, the SLN positivity rate of patients with negative FNAC results (false-negative rate for FNAC) in the neoadjuvant group was lower than that in the primary surgery group (3.0% vs. 33.2%; p < 0.001). After a median follow-up of 3 years, one axillary nodal recurrence was observed, which was a case from the neoadjuvant non-FNAC group. None of the patients in the neoadjuvant group with negative FNAC results had axillary recurrence. CONCLUSION: The false-negative rate for FNAC in the primary surgery group was high; however, SLNB was the proper axillary staging procedure for NAC patients who have clinically suspicious AxLN metastases on radiologic examination but negative FNAC results. |
format | Online Article Text |
id | pubmed-10139842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Korean Breast Cancer Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-101398422023-04-29 Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy Takatsuka, Daiki Yoshimura, Akiyo Sawaki, Masataka Hattori, Masaya Kotani, Haruru Kataoka, Ayumi Horisawa, Nanae Ozaki, Yuri Endo, Yuka Nozawa, Kazuki Iwata, Hiroji J Breast Cancer Original Article PURPOSE: Fine-needle aspiration cytology (FNAC) of axillary lymph nodes (AxLNs) is performed to diagnose nodal metastasis in patients with breast cancer. Although the sensitivity of ultrasound-guided FNAC for identifying AxLN metastasis is in the range of 36%–99%, whether sentinel lymph node biopsy (SLNB) should be performed for neoadjuvant chemotherapy (NAC) patients with negative FNAC results is uncertain. This study aimed to determine the role of FNAC before NAC in the evaluation and management of AxLN in early breast cancer patients. METHODS: We retrospectively analyzed 3,810 clinically node-negative (a lymph node with no clinical metastasis without FNAC or radiological suspicion of metastasis with negative FNAC results) patients with breast cancer who underwent SLNB between 2008 and 2019. We compared the positivity rate of sentinel lymph nodes (SLNs) between patients who received and those who did not receive NAC with negative FNAC results or without FNAC and axillary recurrence rate in the neoadjuvant group with negative SLNB results. RESULTS: In the non-neoadjuvant (primary surgery) group, the positivity rate of SLNs in patients with negative FNAC results was higher than that in patients without FNAC (33.2% vs. 12.9%; p < 0.001). However, the SLN positivity rate of patients with negative FNAC results (false-negative rate for FNAC) in the neoadjuvant group was lower than that in the primary surgery group (3.0% vs. 33.2%; p < 0.001). After a median follow-up of 3 years, one axillary nodal recurrence was observed, which was a case from the neoadjuvant non-FNAC group. None of the patients in the neoadjuvant group with negative FNAC results had axillary recurrence. CONCLUSION: The false-negative rate for FNAC in the primary surgery group was high; however, SLNB was the proper axillary staging procedure for NAC patients who have clinically suspicious AxLN metastases on radiologic examination but negative FNAC results. Korean Breast Cancer Society 2023-03-17 /pmc/articles/PMC10139842/ /pubmed/37051648 http://dx.doi.org/10.4048/jbc.2023.26.e13 Text en © 2023 Korean Breast Cancer Society https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Takatsuka, Daiki Yoshimura, Akiyo Sawaki, Masataka Hattori, Masaya Kotani, Haruru Kataoka, Ayumi Horisawa, Nanae Ozaki, Yuri Endo, Yuka Nozawa, Kazuki Iwata, Hiroji Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy |
title | Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy |
title_full | Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy |
title_fullStr | Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy |
title_full_unstemmed | Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy |
title_short | Evaluation of the Role of Axillary Lymph Node Fine-Needle Aspiration Cytology in Early Breast Cancer With or Without Neoadjuvant Chemotherapy |
title_sort | evaluation of the role of axillary lymph node fine-needle aspiration cytology in early breast cancer with or without neoadjuvant chemotherapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139842/ https://www.ncbi.nlm.nih.gov/pubmed/37051648 http://dx.doi.org/10.4048/jbc.2023.26.e13 |
work_keys_str_mv | AT takatsukadaiki evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy AT yoshimuraakiyo evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy AT sawakimasataka evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy AT hattorimasaya evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy AT kotaniharuru evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy AT kataokaayumi evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy AT horisawananae evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy AT ozakiyuri evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy AT endoyuka evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy AT nozawakazuki evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy AT iwatahiroji evaluationoftheroleofaxillarylymphnodefineneedleaspirationcytologyinearlybreastcancerwithorwithoutneoadjuvantchemotherapy |